Clik here to view.
Guest post : Why the compulsory licence to Natco is a bad idea
I’d like to introduce a guest post from Ranga Iyer, former MD of Wyeth Limited and a drug industry veteran. He is currently an independent advisor to Indian and foreign drug companies on strategy,...
View ArticleClik here to view.
Beyond Glivec : Balancing innovation and public health
I’d like to introduce a guest column by Dr Kristina Lybecker, Associate Professor of Economics at Colorado College in Colorado Springs. Kristina is an economist with a PhD from the University of...
View ArticleClik here to view.
Guest column : Indian patent rulings and impact on emerging economies
Recent Indian patent rulings, as well as those to come, are changing the intellectual property rights (IPR) landscape for emerging economies. They are watched with keen interest by other developing...
View ArticleClik here to view.
Guest column on India & drug patents: Can the US force policy change?
The pharma giant Pfizer wants the US government to act more aggressively to defend the interests of the research-based pharmaceutical sector in India. Will it succeed? The path from lobbying in...
View ArticleClik here to view.
What does Glivec ruling imply for generics? My piece in Sunday ET
In case some of you were waiting for Apothecury’s take on the Glivec judgement, I was waiting for this piece that I did for the Sunday Economic Times to be published. In a nutshell, in the article I...
View Article
